TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
TScan Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.21−0.02 (-9.00%)
Close on Oct 19, 2026
- Market cap
- $27.32M
- P/E (TTM)
- –
- Dividend yield
- –
TScan Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Market Cap | $14.25M | $166.30M |
| Enterprise Value | -$53.13M | $88.19M |
| PS Ratio | 2.00 | 3.65 |
| PB Ratio | 0.21 | 2.03 |
| P/TBV Ratio | 0.21 | 2.29 |
Enterprise value
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -7.47 | 2.51 |
Income (trailing twelve months)
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Revenue | $7.11M | $58.34M |
| Operating Income | -$120.54M | -$21.40M |
| Net Income | -$117.71M | -$22.46M |
| EBITDA | -$120.54M | -$16.91M |
| EPS (Diluted) | -$0.91 | -$0.83 |
Margins
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -1695.1% | -44.0% |
| Profit Margin | -1655.3% | -40.2% |
| EBITDA Margin | -1695.1% | -30.2% |
| FCF Margin | -1665.6% | -9.27% |
Returns
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -95.8% | -53.2% |
| Return on Assets (ROA) | -50.1% | -40.9% |
| Return on Capital Employed (ROCE) | -85.8% | -38.1% |
Growth
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 2.15% | 5.96% |
| Revenue Growth (3Y CAGR) | -8.63% | 2.25% |
| Revenue Growth (5Y CAGR) | 56.9% | 6.48% |
Balance sheet
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $100.16M | $61.43M |
| Total Debt | $32.78M | $118.52M |
| Net Cash (Debt) | $67.38M | $15.35M |
| Net Cash Per Share | $0.99 | $0.66 |
| Equity (Book Value) | $69.02M | $49.09M |
| Book Value Per Share | $1.02 | $1.37 |
| Tangible Book Value | $69.02M | $23.52M |
| Working Capital | $73.44M | $76.81M |
Financial position
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 3.37 | 3.34 |
| Quick Ratio | 3.23 | 2.44 |
| Debt / Equity | 0.47 | 0.52 |
| Interest Coverage | -43.22 | -6.26 |
Cash flow (trailing twelve months)
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$116.28M | -$12.35M |
| Capital Expenditures | -$2.16M | -$1.08M |
| Free Cash Flow | -$118.44M | -$20.22M |
| FCF Per Share | -$1.75 | -$0.42 |
Efficiency
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.03 | 0.39 |
| Revenue Per Employee | $50.08K | $404.87K |
| Profits Per Employee | -$828.96K | -$703.34K |
| Employee Count | 142 | 74 |
Dividends and yields
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -826.2% | -23.3% |
| FCF Yield | -831.3% | -8.72% |
Shares
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 67,779,300 | 58,127,000 |
| Shares Change (YoY) | 4.13% | 10.9% |
| Float | 46,811,300 | 49,136,700 |
| Shares Held by Insiders | 30.9% | 11.6% |
| Shares Held by Institutions | 53.5% | 59.4% |
Scores
| Measure | TScan Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -6.29 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from TScan Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.